Technical Analysis for APRE - Aprea Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 6.55 | 5.82% | 0.36 |
Earnings due: Mar 28
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 50 DMA | Bullish | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Centerline Cross | Bearish | 5.82% | |
Wide Bands | Range Expansion | 5.82% | |
Gapped Up | Strength | 5.82% | |
Oversold Stochastic | Weakness | 5.82% | |
Calm After Storm | Range Contraction | 23.35% | |
Wide Bands | Range Expansion | 23.35% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 12 hours ago |
Up 5% | about 12 hours ago |
Rose Above Previous Day's High | about 14 hours ago |
Rose Above 50 DMA | about 14 hours ago |
2x Volume Pace | about 14 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/28/2024
Aprea Therapeutics, Inc. Description
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.8465 |
52 Week Low | 2.78 |
Average Volume | 40,560 |
200-Day Moving Average | 4.43 |
50-Day Moving Average | 6.27 |
20-Day Moving Average | 7.01 |
10-Day Moving Average | 6.76 |
Average True Range | 0.78 |
RSI (14) | 49.49 |
ADX | 29.74 |
+DI | 22.36 |
-DI | 25.47 |
Chandelier Exit (Long, 3 ATRs) | 6.50 |
Chandelier Exit (Short, 3 ATRs) | 7.39 |
Upper Bollinger Bands | 8.83 |
Lower Bollinger Band | 5.19 |
Percent B (%b) | 0.37 |
BandWidth | 51.88 |
MACD Line | -0.02 |
MACD Signal Line | 0.22 |
MACD Histogram | -0.2371 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 8.05 | ||||
Resistance 3 (R3) | 7.96 | 7.38 | 7.80 | ||
Resistance 2 (R2) | 7.38 | 6.99 | 7.42 | 7.72 | |
Resistance 1 (R1) | 6.96 | 6.76 | 7.17 | 7.05 | 7.63 |
Pivot Point | 6.38 | 6.38 | 6.48 | 6.42 | 6.38 |
Support 1 (S1) | 5.96 | 5.99 | 6.17 | 6.05 | 5.47 |
Support 2 (S2) | 5.38 | 5.76 | 5.42 | 5.38 | |
Support 3 (S3) | 4.96 | 5.38 | 5.30 | ||
Support 4 (S4) | 5.05 |